Please use this identifier to cite or link to this item: http://hdl.handle.net/10637/15666

Chalcones as Promising Lead Compounds on Cancer Therapy


See/Open:
 CurrMedChem_2015.pdf
841,97 kB
Adobe PDF
Title: Chalcones as Promising Lead Compounds on Cancer Therapy
Authors : León-González, Antonio J.
Acero de Mesa, Nuria
Muñoz Mingarro, Dolores
Navarro Zafra, Inmaculada
Martín-Cordero, Carmen
Keywords: ApoptosisCancerChalconeChemopreventionFlavonoidSynthesisTubulin
Publisher: Bentham Science Publishers
Citation: León-González AJ, Acero N, Muñoz-Mingarro D, Navarro I, Martín-Cordero C. Chalcones as Promising Lead Compounds on Cancer Therapy. Curr Med Chem. 2015;22(30):3407-25. doi: 10.2174/0929867322666150729114829
Abstract: Chalcones constitute a group of phenolic compounds that command an increasing interest on cancer research. Natural chalcones are widespread through the plant kingdom. The most abundant and investigated chalcones are isoliquiritigenin, flavokawain and xanthohumol, which are present in the Fabaceae, Piperaceae, Cannabaceae, and Moraceae families. These chalcones have been shown to be promising lead antitumor-chemopreventive drugs by three different activities: antioxidants, cytotoxic and apoptosis inducers. In recent years, SAR (structure-activity relationship) has contributed towards the improvement of anticancer properties of chalcones by substituting aryl rings and introducing heterocyclic moieties. This review summarizes the anticancer activities shown by natural chalcones and the SAR and describes how different chemical moiety modifications could lead them to be therapeutically useful in the treatment of cancer.
Description: Versión en acceso abierto siguiendo política de la revista
URI: http://hdl.handle.net/10637/15666
Rights : http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
ISSN: 1875-533X
Issue Date: 2015
Center : Universidad San Pablo-CEU
Appears in Collections:Facultad de Farmacia





Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.